---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-277513"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-06-22T20:05:37+00:00"
generated_at: "2026-06-22T20:09:33.234335+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Director Michelle Doig resigns; shareholders elect two Class I directors at annual meeting

## Summary
- Michelle Doig resigned as Class I director upon completion of her term on June 16, 2026; resignation not due to any disagreement.
- Shareholders elected Peter Lebowitz (31,822,504 votes for) and Frank McCormick (25,654,119 votes for) as Class I directors.
- Ratification of Deloitte & Touche LLP as independent auditor for FY 2026 approved with 34,535,875 votes for.

## SEC filing metadata
- accession: 0001193125-26-277513
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-06-22T20:05:37+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526277513/0001193125-26-277513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526277513/d137002d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-277513
- JSON: https://secwatch.observer/filing/0001193125-26-277513.json
- Plain text: https://secwatch.observer/filing/0001193125-26-277513.txt

## Key facts
- Executive change
  Michelle Doig resigned as Class I director at BridgeBio Oncology Therapeutics, Inc..
  - Action: resigned
  - Role: Class I director
  source text: On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the “Company”), of her resignation as a member of the Board of Directors of the Company (the “Board”) upon the completion of her term as a Class I director, effective as of June 16, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000119312526277513/0001193125-26-277513-index.htm
- Shareholder Votes
  BridgeBio Oncology Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: Proposal 1 - Election of Directors. The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld Peter Lebowitz, M.D., Ph.D. 31,822,504 3,372 Frank P. McCormick, Ph.D., F.R.S., D. Sc. 25,654,119 6,171,757 There were 2,713,439 broker non-votes and 13,805,126 no votes regarding this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000119312526277513/0001193125-26-277513-index.htm
- Shareholder Votes
  BridgeBio Oncology Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2026-06-16 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-16
  source text: Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm. The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions 34,535,875 3,440 0 There were zero broker non-votes and 13,805,126 no votes regarding this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000119312526277513/0001193125-26-277513-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.